- Home
- XERS vs FMBH Comparison
XERS vs FMBH Comparison
Compare XERS & FMBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | XERS | FMBH |
|---|---|---|
| Founded | 2005 | 1865 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | XERS | FMBH |
|---|---|---|
| Price | $6.28 | $43.57 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | $10.83 | ★ $43.40 |
| AVG Volume (30 Days) | ★ 1.2M | 76.5K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 2.33% |
| EPS Growth | ★ 100.00 | 16.06 |
| EPS | N/A | ★ 3.83 |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $34.37 | $9.30 |
| Revenue Next Year | $22.86 | $6.66 |
| P/E Ratio | ★ N/A | $11.38 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.30 | $33.67 |
| 52 Week High | $10.08 | $44.85 |
Technical Indicators
Market Signals| Indicator | XERS | FMBH |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 58.56 |
| Support Level | $6.26 | $42.36 |
| Resistance Level | $6.41 | $44.50 |
| Average True Range (ATR) | 0.20 | 0.84 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 71.38 | 80.51 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About FMBH First Mid Bancshares Inc.
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.